Plain-English translation of NCT07660614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called , which is delivered directly into the fluid around your spinal cord through an injection. The medication is designed to target a specific protein involved in ALS. Researchers want to find the right dose and see if this treatment is safe and might help slow down the disease.
ALS is a progressive disease that gradually weakens muscles, and current treatment options are limited. This medication represents a new approach that has not been tested in humans before, and researchers hope it may offer a new way to help people with ALS.
You likely qualify if…
You likely don't qualify if…
You would visit the study site 9 times over several months and stay overnight once. The research team would perform physical exams, check your heart rhythm, take blood and urine samples, and collect fluid from around your spinal cord. You would also have tests to measure your lung function, speech, and muscle strength. At one visit, you would receive an injection of either the study medication or a placebo directly into the fluid around your spinal cord. Between visits, you would have phone or video check-ins with the study staff.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Germany
Italy
Netherlands
Sweden